S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
TRVI · Trevi Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Trevi Therapeutics Inc (TRVI)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$12.77
-0.04
(-0.31%)
● At close: October 21 at 4:00:00 PM EDT
$12.63
-0.14
(-1.10%)
Overnight:
8:07:26 PM EDT
DAY'S RANGE
$12.77
$12.76
$13.30
52-WEEK RANGE
$12.77
$9.82
$20.22
What's happening
- TRVI is down 0.31% today, trading at $12.77. — Live quote
- Volume today (157,112) is well below its 3-month average of 2,303,180. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.11 actual vs. $-0.11 estimated (+2.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 11
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
TRVI
+2.48%
vs S&P 500
-10.30%
1-YEAR RETURN
TRVI
+20.02%
vs S&P 500
+5.46%
6-MONTH RETURN
TRVI
-11.76%
3-MONTH RETURN
TRVI
-29.43%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.11
Est. $-0.11
BEAT +2.2%
2026-04-26 (Q1 2026)
$-0.09
Est. $-0.08
MISS -15.4%
2026-01-26 (Q4 2025)
$-0.06
Est. $-0.10
BEAT +40.1%
2025-10-26 (Q3 2025)
$-0.08
Est. $-0.10
BEAT +20.2%
Valuation Measures & Ratios
Enterprise Value4$1.78B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book78.24
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-23.59%
Return on Assets (ROA9)-22.64%
Avg Volume (3M)2,303,180
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $3.01B | $1.75B | $1.35B | $746.9M | $720.4M |
| P/E | -54.73 | -36.71 | -28.34 | -15.49 | -15.38 |
| Price/Book | 9.38 | 10.16 | 7.12 | 3.76 | 7.24 |
| EV/EBITDA | -47.06 | -32.10 | -24.40 | — | — |
| ROE | -17.14% | -27.67% | -25.13% | -24.30% | -47.09% |
| ROA | -16.67% | -26.52% | -23.92% | -23.15% | -43.77% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short14,639,150
Change from Prior Settlement+21.28%
% of Float—
Days to Cover (Short Ratio)8.33
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +20.0%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-09-17; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on TRVI
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$20.5M | -$14.9M | -$13.9M | -$13.7M | -$11.5M | -$14.1M | -$13.3M | -$11.9M |
| Net income | -$17.8M | -$13.2M | -$11.8M | -$12.3M | -$10.3M | -$13.2M | -$12.4M | -$10.9M |
| EPS (diluted) | $-0.11 | $-0.09 | $-0.08 | $-0.09 | $-0.09 | $-0.13 | $-0.12 | $-0.11 |
| EPS (basic) | $-0.11 | $-0.09 | $-0.08 | $-0.09 | $-0.09 | $-0.13 | $-0.12 | $-0.11 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $330.5M | $179.6M | $193.4M | $199.4M | $208.3M | $107.0M | $110.9M | $68.9M |
| Total liabilities | $9.0M | $7.5M | $10.2M | $9.6M | $9.8M | $7.5M | $11.3M | $9.9M |
| Stockholders' equity | $321.5M | $172.1M | $183.2M | $189.8M | $198.5M | $99.5M | $99.6M | $59.0M |
| Total current assets | $325.7M | $176.1M | $191.7M | $198.3M | $207.2M | $105.6M | $109.4M | $67.3M |
| Total current liabilities | $8.7M | $7.1M | $9.7M | $9.0M | $9.2M | $6.9M | $10.5M | $9.1M |
| Cash & equivalents | $54.3M | $19.4M | $18.9M | $56.9M | $117.1M | $19.4M | $34.1M | $16.1M |
| Marketable securities (current) | $264.6M | $152.4M | $169.3M | $138.1M | $86.8M | $83.9M | $73.5M | $49.4M |
| Other current assets | $2.6M | $2.1M | $2.1M | $2.0M | $1.6M | $834.0K | $867.0K | $667.0K |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $336.0K | $265.0K | $178.0K | $213.0K | $239.0K | $277.0K | $157.0K | $174.0K |
| Other non-current assets | $3.9M | $2.6M | $928.0K | $103.0K | $68.0K | $241.0K | $243.0K | $256.0K |
| Accounts payable | $3.1M | $2.2M | $3.9M | $2.7M | $3.0M | $1.4M | $3.4M | $1.6M |
| Accrued liabilities | $5.3M | $4.6M | $5.5M | $6.0M | $6.0M | $5.2M | $6.8M | $7.2M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $142.0K | $128.0K | $128.0K | $128.0K | $122.0K | $100.0K | $94.0K | $75.0K |
| Retained earnings | -$360.8M | -$343.0M | -$329.8M | -$321.5M | -$309.7M | -$297.4M | -$287.0M | -$275.6M |
| Accumulated other comprehensive income (loss) | -$425.0K | -$190.0K | $148.0K | $30.0K | $24.0K | $73.0K | $61.0K | $139.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.4M | -$16.7M | -$7.6M | -$10.9M | -$10.1M | -$13.5M | -$9.6M | -$9.6M |
| Investing cash flow | -$112.0M | $17.0M | -$30.6M | -$50.9M | -$2.6M | -$10.0M | -$23.9M | $7.7M |
| Financing cash flow | $164.4M | $222.0K | $284.0K | $1.6M | $110.4M | $8.7M | $51.5M | $5.0M |
| Free cash flow | -$17.6M | -$16.8M | -$7.6M | -$10.9M | -$10.1M | — | -$9.6M | -$9.6M |
| Capital expenditures | $124.0K | $102.0K | $0 | $12.0K | $0 | — | $7.0K | $0 |
| Depreciation & amortization | $34.0K | $34.0K | $31.0K | $38.0K | $38.0K | $37.0K | $38.0K | $36.0K |
| Share-based compensation | $3.3M | $2.2M | $4.0M | $1.2M | $1.4M | $1.2M | $2.9M | $822.0K |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$276.0K | -$1.5M | $123.0K | -$282.0K | $1.6M | -$2.0M | $1.8M | $130.0K |
| Purchases of investments | $153.6M | $8.5M | $54.4M | $71.6M | $17.1M | $27.5M | $45.2M | $13.0M |
| Sales/maturities of investments | $41.6M | $25.6M | $23.8M | $20.7M | $14.5M | $17.6M | $21.3M | $20.7M |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$49.3M | -$51.5M | -$33.9M | -$29.9M | -$32.5M |
| Net income | -$42.8M | -$47.9M | -$29.1M | -$29.2M | -$33.9M |
| EPS (diluted) | $-0.32 | $-0.47 | $-0.29 | $-0.45 | $-1.49 |
| EPS (basic) | $-0.32 | $-0.47 | $-0.29 | $-0.45 | $-1.49 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $193.4M | $110.9M | $89.4M | $123.0M | $38.5M |
| Total liabilities | $10.2M | $11.3M | $6.9M | $15.6M | $21.4M |
| Stockholders' equity | $183.2M | $99.6M | $82.5M | $107.5M | $17.1M |
| Total current assets | $191.7M | $109.4M | $87.5M | $122.6M | $38.0M |
| Total current liabilities | $9.7M | $10.5M | $5.8M | $13.4M | $12.7M |
| Cash & equivalents | $18.9M | $34.1M | $32.4M | $12.6M | $36.8M |
| Marketable securities (current) | $169.3M | $73.5M | $50.6M | $107.9M | — |
| Other current assets | $2.1M | $867.0K | $955.0K | $1.3M | $241.0K |
| Property, plant & equipment | $178.0K | $157.0K | $216.0K | $170.0K | $53.0K |
| Other non-current assets | $928.0K | $243.0K | $297.0K | $205.0K | $334.0K |
| Accounts payable | $3.9M | $3.4M | $1.8M | $2.9M | $2.8M |
| Accrued liabilities | $5.5M | $6.8M | $3.7M | $3.5M | $3.8M |
| Other non-current liabilities | — | — | — | $3.0K | — |
| Common stock & paid-in capital | $128.0K | $94.0K | $68.0K | $60.0K | $29.0K |
| Retained earnings | -$329.8M | -$287.0M | -$239.1M | -$210.1M | -$180.9M |
| Accumulated other comprehensive income (loss) | $148.0K | $61.0K | -$29.0K | -$122.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$42.1M | -$38.3M | -$31.7M | -$28.2M | -$28.9M |
| Investing cash flow | -$94.1M | -$21.5M | $59.4M | -$107.4M | — |
| Financing cash flow | $121.0M | $61.5M | -$7.9M | $111.3M | $20.8M |
| Free cash flow | -$42.1M | -$38.3M | -$31.8M | -$28.3M | — |
| Capital expenditures | $12.0K | $35.0K | $137.0K | $159.0K | — |
| Depreciation & amortization | $144.0K | $147.0K | $123.0K | $43.0K | — |
| Share-based compensation | $5.2M | $3.6M | $2.2M | $2.3M | $2.5M |
| Change in accounts receivable | — | — | — | — | — |
| Change in accounts payable | -$598.0K | $1.6M | -$1.0M | $9.0K | $831.0K |
| Purchases of investments | $170.7M | $98.5M | $9.9M | $126.2M | — |
| Sales/maturities of investments | $76.6M | $77.0M | $69.5M | $19.0M | — |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | $5.8M | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding TRVI as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-03-21 to 2026-09-15
Recent transactions
- Insiders have net sold 39,473 shares over the last 182 days, across 0 purchases and 4 sales.
- Most recent: Heffernan Michael Thomas (Reporting person) — Option exercise of 18,421 shares on 2026-09-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)39,473 sh(4 txns)
Net Shares-39,473
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Heffernan Michael Thomas | Reporting person | Option exercise | 2026-09-15 | 18,421 |
| Galletta Christopher | See Remarks | Option exercise | 2025-12-02 | 4,225 |
| SCIASCIA THOMAS | Chief Scientific Officer | Option exercise | 2025-03-25 | 2,631 |
| GOOD JENNIFER L | President & CEO | Option exercise | 2025-03-21 | 5,263 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-15 | Heffernan Michael Thomas | Reporting person | Option exercise | 18,421 | $3.04 |
| 2026-09-15 | Heffernan Michael Thomas | Reporting person | Open market sale | 18,321 | $15.09 |
| 2026-09-15 | Heffernan Michael Thomas | Reporting person | Open market sale | 100 | $15.88 |
| 2026-09-15 | Heffernan Michael Thomas | Reporting person | Option exercise | 21,052 | $3.33 |
| 2026-09-15 | Heffernan Michael Thomas | Reporting person | Open market sale | 20,952 | $15.09 |
| 2026-09-15 | Heffernan Michael Thomas | Reporting person | Open market sale | 100 | $15.88 |
| 2025-12-02 | Galletta Christopher | See Remarks | Option exercise | 4,225 | $0.51 |
| 2025-03-25 | SCIASCIA THOMAS | Chief Scientific Officer | Option exercise | 2,631 | $1.43 |
| 2025-03-25 | SCIASCIA THOMAS | Chief Scientific Officer | Open market sale | 2,631 | $6.60 |
| 2025-03-21 | GOOD JENNIFER L | President & CEO | Option exercise | 5,263 | $1.43 |
| 2025-03-21 | GOOD JENNIFER L | President & CEO | Open market sale | 5,263 | $6.58 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:47 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-17 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 8-K | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-05-05 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-05 | 8-K | 2026-05-05 | View on SEC.gov → |
| 2026-04-17 | 8-K | 2026-04-16 | View on SEC.gov → |
Recent news
Headlines about TRVI (Trevi Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
(TRVI) Dynamic Trading Report (TRVI:CA)
Stock Traders Daily · 2026-10-20 -
Liquidity Mapping Around (TRVI) Price Events
Stock Traders Daily · 2026-10-19 -
Trevi Therapeutics (TRVI) Institutional Ownership 2026 $TRVI
MarketBeat · 2026-10-15 -
Do Trevi Therapeutics’ (TRVI) CORAL Data and GSK’s Exit Reframe Its Chronic Cough Ambitions?
Yahoo · 2026-10-13 -
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
Yahoo · 2026-10-13 -
Trevi Therapeutics Announces Results From Phase 2b CORAL Trial Accepted As Oral Presentation At CHEST 2026 Annual Meeting Of American College Of Chest Physicians
Benzinga · 2026-10-13 -
Trevi Therapeutics Q2 2026 Earnings Call Transcript
Benzinga · 2026-10-12 -
Top 4 Healthcare Stocks Backed by Raymond James Analysts
Yahoo · 2026-10-08
No headlines in this category right now — try “All”.